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ABSTRACT
Background Non-alcoholic fatty liver disease 
(NAFLD) is a chronic l iver disease related to 
metabolic syndrome, which can progress to liver cir-
rhosis. Standard medication has not been established. 
Pemafibrate is a selective peroxisome proliferator-
activated receptor (PPAR) α modulator. We retrospec-
tively evaluated the efficacy of pemafibrate in patients 
with NAFLD.
Methods We retrospectively enrolled 17 patients (ten 
men, seven women; median age, 63 years; range, 27–81 
years). They were all proven to have fatty liver through 
imaging and had little or no history of drinking (ethanol 
consumption of < 20 g/day for women and < 30 g/day 
for men). They were administered pemafibrate from 
October 2018 to June 2020.
Results After administration, serum triglyceride 
(TG) tended to be decreased (300.5 ± 22.5 to 239.5 ± 
34.3 mg/dL, P = 0.06). Serum high-density lipoprotein 
(HDL) cholesterol and low-density lipoprotein (LDL) 
cholesterol levels did not change. ALT was significantly 
decreased (–47.4%) for six months (57.5 ± 8.8 to 30.3 ± 
5.8 U/L, P < 0.01). The values of serum GGT signifi-
cantly decreased (–48.7%) for sixth months (63.9 ± 10.3 
to 32.8 ± 6.6 U/L, P < 0.01). Aspartate aminotransferase 
(AST) to platelet ratio (APRI), a fibrosis marker, also 
was significantly decreased in the sixth month (0.7 ± 
0.1 to 0.4 ± 0.1, P < 0.05). Body mass index (BMI) and 
hemoglobin A1c (HbA1c) showed no significant change.
Conclusion Pemafibrate dramatically ameliorated the 
values of liver function tests and APRI in patients with 
NAFLD.
Key words non-alcoholic fatty liver disease; non- 
alcoholic steatohepatitis; pemafibrate; liver function; 
liver fibrosis
Non-alcoholic fatty liver disease (NAFLD), including 
steatohepatitis (NASH), has emerged as a common 
public health problem in recent decades. The overall 
global prevalence of NAFLD diagnosed by imaging is 
estimated at around 25%.1 It is also increasing in the 
Asia-Pacific region.2 The treatment for NAFLD consists 
of a variety of strategies, including lifestyle modification 
and several drugs such as metabolism ameliorator, anti-
inflammatory agents, and antifibrotic agents. However, 
the recommended pharmacotherapies are extremely 
limited, and vitamin E or pioglitazone are indicated 
only for a certain limited number of patients according 
to the guidelines.3 The standard medication for NAFLD 
has not yet been established.
Peroxisome proliferator-activated receptors 
(PPARs) form a subfamily of the nuclear receptor 
superfamily.4 There are three different types of PPAR 
(α, δ, and γ). Among them, PPARα (nuclear receptor 
subfamily 1, group C, member 1, NR1C1) is a ligand-
activated nuclear receptor highly expressed in the 
liver. PPARα was initially identified as the molecular 
target of xenobiotics inducing peroxisome proliferation 
in rodents.5 PPARα has been well-established as a 
critical modulator of lipid transport and metabolism, 
notably mitochondrial and peroxisomal fatty acid beta-
oxidation.6 It negatively regulates pro-inflammatory and 
acute phase response signaling pathways.7 Modulating 
PPARα has been considered as the key to treating meta-
bolic disease, including NAFLD.8
Pemafibrate (K-877, Parmodia® tablet, Kowa 
Company, Ltd., Nagoya, Japan), a selective PPARα 
modulator (SPPARMα), was approved in July 2017 and 
released in June 2018 in Japan. In Japan, phase 2 and 3 
trials demonstrated that pemafibrate significantly ame-
liorated lipid abnormalities in patients with dyslipidemia 
without increasing adverse effects.9, 10 A large-scale 
trial, PROMINENT, for dyslipidemic patients with type 
2 diabetes (T2DM) is now ongoing.11
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Pemafibrate, which improves liver pathology in 
the diet-induced rodent model of NASH,12 is expected 
to become a promising therapeutic agent for human 
NASH. However, the efficacy of pemafibrate in patients 
with NAFLD has not yet been reported.
Serum aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) values have long been 
used as surrogate markers for liver injury.13, 14 ALT is 
also a marker for hepatocyte death, and predicts the 
presence of liver fibrosis and risk for fibrosis progression 
in NASH.15 It has also been reported that normaliza-
tion of ALT levels after intervention is associated with 
fibrosis improvement in NASH.16, 17 On the other hand, 
gamma-glutamyl transpeptidase (GGT) levels indirectly 
reflect the oxidative stress related to the glutathione 
levels in the liver.18 Oxidative stress is the core patho-
genesis of NAFLD.19 Therefore, reducing the values 
of serum liver function tests (LFTs) (mainly ALT and 
GGT) is considered as a predictive factor of long-term 
treatment success in NAFLD.
In this study, we aimed to evaluate the efficacy 
of pemafibrate on LFTs in patients with NAFLD 
retrospectively.
SUBJECTS AND METHODS
This was a single-center retrospective observational 
study. Between October 2018 and June 2020, a total 
of 77 patients in our hospital that were administered 
pemafibrate were enrolled. Then, only patients with 
fatty liver proven by imaging (urtrasonography; US, 
computed tomography; CT, or magnetic resonance of 
imaging; MRI) were selected (Figs. 1A, B, C and D) 
for the study. Patients who had other causes for chronic 
hepatitis (hepatitis B virus, hepatitis C virus, autoim-
mune hepatitis, primary biliary cholangitis) were not 
enrolled.
Table 1 demonstrates the definition of fatty liver by 
imaging.20 Patients who discontinued pemafibrate for 
Fig. 1. Representative images of fatty liver. (A) Ultrasonography demonstrated higher echogenicity of the liver than the 
renal cortex, (B) Unenhanced computed tomography demonstrated lower density than the spleen, Magnetic resonance of 
imaging demonstrated the signal loss on (C) out-of-phase compared with (D) in-phase imaging.
190
S. Ikeda et al.
© 2020 Tottori University Medical Press
any reason, had a history of drinking (ethanol consump-
tion of > 20 g/day for women and > 30 g/day for men), 
and short duration of using pemafibrate (< 3 months) 
were excluded from the study. Finally, we selected 17 
patients (ten men, seven women) (Fig. 2). We obtained 
each patient’s information concerning gender, age, 
height, and body weight, and then calculated body mass 
index (BMI), both pre-treatment and most recent. We 
also collected the information about concomitant medi-
cations, which are considered useful for NAFLD/NASH 
treatment as follows; dipeptidyl peptidase-4 (DPP4) 
inhibitor, metformin, sodium-glucose cotransporter 
2 (SGLT2) inhibitor, ursodeoxycholic acid (UDCA), 
eicosapentaenoic acid (EPA), statin, and ezetimibe. 
Fasting laboratory data [triglyceride (TG), high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, AST, ALT, GGT, fibrosis index 
based on the four factors (FIB-4) index using age, AST, 
ALT and platelet values,21–23 AST to platelet ratio index 
(APRI)24, 25] were collected and calculated as well. Six 
months were selected for the median duration of treat-
ment. Missing values were inputted using the median of 
pre- and post values.
Statistical analysis
The Friedman test and Dunn’s test were applied for 
multiple paired comparisons. The Wilcoxon test 
was applied for comparing two paired groups. The 
Mann-Whitney test was applied for comparing two 
independent groups. One-way ANOVA was applied 
for comparing three independent groups. All statistical 
tests were performed using StatFlex (Windows ver. 6.0; 
Table 1. The definition of fatty liver on imaging
Modalities Definition
US (1) Increased echogenicity, hepatomegaly, and intra-hepatic vascular blurring. 
(2) Higher echogenicity than renal cortex 
(1) and/ or (2)
CT An unenhanced CTL-S (ratio of liver to splenic attenuation values) of less than 1 HU.
MRI The signal loss on out-of-phase (OP) compared with in-phase (IP) imaging.
CT, computed tomography; MRI, magnetic resonance imaging; HU, Hounsfield Unit; US, ultrasonography.
Fig. 2. Flow-chart of patient selection. Initially, there were seventy-seven eligible patients. Forty-one patients were not enrolled because 
they had not been proven to have fatty liver through imaging. Patients with other causes of chronic hepatitis were also not enrolled. 
Patients who stopped pemafibrate for any reason, and/or with a history of drinking and short duration of using pemafibrate were ex-
cluded from the study. Seventeen patients were ultimately selected for this study.
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Artech, Osaka, Japan). Values are expressed as median 
(range) or mean with a standard error of the mean (SEM). 
Statistical significance was set at P < 0.05.
Ethical Considerations
The study protocol was approved by the Institutional 
Review Board of our institute (No. 20A070) under the 
guidelines of the 1975 Declaration of Helsinki.
RESULTS
Baseline characteristics of the patients
The baseline characteristics of the patients are presented 
in Table 2. The median age of patients was 63 years; 
range, 27–81 years. Ten patients had T2DM (58.8%). 
Ten patients (58.8%), six patients (35.3%), and one 
patient (5.9%) were proven to have fatty liver by US, 
CT, and MRI, respectively. Three patients had been 
previously proven to have NASH by liver biopsy. Pre-
treatment laboratory values as follows; TG 300.5 ± 
22.5 mg/dL, HDL-cholesterol 46.5 ± 2.4 mg/dL, LDL-
cholesterol 109.5 ± 10.6 mg/dL, AST 43.8 ± 5.4 U/L, 
ALT 57.4 ± 8.8 U/L, GGT 63.9 ± 10.3 U/L. DPP4 inhibi-
tor, metformin, SGLT2 inhibitor, EPA, statin, ezetimibe, 
and UDCA had been already prescribed in six (35.3%), 
three (17.6%), two (11.8%), three (17.6%), five (29.4%), 
seven (41.2%) and four (23.5%) patients, respectively. 
Three patients (17.6%) were given 0.1 mg bid (twice-
daily), twelve (70.6%), 0.2 mg bid, and two (11.8%), 
0.4 mg bid of pemafibrate, respectively. The dosage of 
pemafibrate was selected according to pre-treatment 
serum TG levels (0.1 mg: 0.2 mg: 0.4 mg = 275.3 ± 41.0: 
298.0 ± 29.2: 353.5 ± 10.3 mg/dL). The median dura-
tion of administration was 6.1 months; range, 3.0–19.1 
months.
Serum TG tended to be decreased (–12.4%) 
(300.5 ± 22.5 to 239.5 ± 34.3 mg/dL, P = 0.06) for 
six months (Fig. 3A). The serum HDL cholesterol 
levels and LDL cholesterol did not change (46.5 ± 
2.4 to 44.6 ± 1.5 mg/dL; 109.5 ± 10.6 to 124.7 ± 19.0 
mg/dL) (Figs. 3B and C). The values of serum AST 
decreased (–34.2%); however, there is no statisti-
cal significance (43.8 ± 5.4 to 28.5 ± 2.7 U/L, P = 
0.23) (Fig. 3D). ALT was significantly decreased 
(–47.4%) for six months (57.5 ± 8.8 to 30.3 ± 5.8 U/L, 
P < 0.01) (Fig. 3E). The values of serum GGT were 
significantly decreased (–48.7%) for six months (63.9 
± 10.3 to 32.8 ± 6.6 U/L, P < 0.01) (Fig. 2F). BMI (26.8 
± 1.0 to 26.1 ± 1.0 kg/m2) and HbA1c (7.7 ± 0.5 to 7.0 
± 0.2 %) did not change for six months (Figs. 4A and 
B). There was no difference in BMI between T2DM 
and non-T2DM patients (25.2 ± 1.3 vs. 25.0 ± 1.4 kg/
m2). There was also no significant change in BMI in 
both groups in the sixth month (25.6 ± 1.2 and 24.4 ± 
1.5 kg/m2). Gender made no difference in the efficacy of 
pemafibrate.
FIB-4 index also did not change in the sixth month 
(1.7 ± 0.2 to 1.4 ± 0.2); on the other hand, APRI was 
significantly decreased in the sixth month (0.7 ± 0.1 to 0.4 
± 0.1, P < 0.05).
Three biopsy-proven NASH patients were admin-
istered 0.2 mg bid of pemafibrate. The median duration 
was 5.6 months; range, 3.7–14.5 months. Serum TG 
and values of LFTs were decreased (AST –41.7%, ALT 
–53.8%, GGT –22.2%) in six months (Figs. 5A, B, C 
and D). APRI was also decreased (1.0 ± 0.2 to 0.5 ± 0.1) 
in three months.
DISCUSSION
In this study, we demonstrated that pemafibrate dramat-
ically ameliorated the values of ALT, GGT, and APRI 
in NAFLD. To our knowledge, this is the first report 
demonstrating the biological effects of pemafibrate in 
humans with NAFLD.
Several trials reported the efficacy of fibrates on 
NAFLD patients. Miranda et al. reported that fenofi-
brate for 48 weeks demonstrated a significant decrease 
in abnormal LFTs (AST; 88 ± 39 to 64 ± 31 U/L, ALT; 
47 ± 23 to 38 ± 12 U/L, GGT; 90 ± 79 to 55 ± 41 U/L) 
in 16 patients, although liver histology did not change 
significantly.26 Gandhi N. et al. also reported that fenofi-
brate treatment for median 0.3 (0.02–2.1) years led to an 
improvement in LFTs (ALT; 43.1 ± 33.5 to 37.5 ± 24.5 
U/L, GGT; 79.5 ± 59.8 to 57.1 ± 43.6 U/L) in 116 pa-
tients.27 The reduction rate (around –20%) of fenofibrate 
on ALT and GGT is lower than our data.
The difference between previously released fibrates 
and pemafibrate is the high selectivity of PPARα. The 
PPARα activation by pemafibrate was reported to be 
> 2,500 times stronger than fenofibric acid because of 
the Y-shaped structure, unlike conventional fibrates.28 
The high selectivity enables pemafibrate to be used at a 
reduced dosage. Fenofibrate administration needs to be 
at least 106.6 mg to 160 mg qd (once-daily); on the other 
hand, only 0.2 to 0.4 mg bid of pemafibrate is needed. 
Although the major excretion route is the liver, the high 
selectivity enables pemafibrate to be used in any under-
lying liver disease except for decompensated cirrhosis 
(Child-Pugh B or C). Moreover, pemafibrate is the first 
fibrate that can be used safely in combination with a 
statin. In this study, five patients had been prescribed a 
statin. There were no differences in LDL cholesterol and 
LFTs between combination and monotherapy groups for 
six months.
In the phase 2 trial, 26 (18%) subjects with fatty 
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liver were administered pemafibrate (among these, 14 
subjects were administered the clinical dose).6 In phase 
3, 58 (53.2%) subjects with fatty liver were administered 
0.2 mg or 0.4 mg bid of pemafibrate; however, there 
were 68 (62.4%) patients with a drinking habit. Since 
these trials did not exclude patients with alcoholic liver 
disease, the effects of pemafibrate on NAFLD could not 
be evaluated.
In phases 2 and 3, subjects with AST or ALT levels 
more than 2- or 3-fold higher than the upper limit of the 
reference range were excluded.6, 7 So our study reports 
the first demonstration of the efficacy of clinical doses 
of pemafibrate for LFTs in patients with NAFLD.
In this study, BMI and HbA1c did not change for 
six months, which indicated that the improvement of 
ALT and GGT was achieved only by PPARα activation. 
We also evaluated the scoring system of fibrosis, and 
only APRI significantly decreased in sixth months 
after treatment with pemafibrate. The mean of ROC 
for APRI was reportedly 0.85 with an optimal cut-off 
of 0.98, giving a sensitivity of 75% and a specificity of 
86%.25 In our study, the mean of APRI was 0.65, and 
only two patients were over 0.98. APRI can reportedly 
distinguish patients with lobular inflammation and 
ballooning from those without.29 Decrease of AST is 
directly considered as an improvement of liver injury 
associated with inflammation. Platelets, another factor 
of APRI, are reported as an active participant in the 
process of liver inflammation.30 Platelets exert potent 
inflammatory effects and play a central part in the 
progression from simple steatosis to NASH.31 Excessive 
platelet consumption is one of the mechanisms of 
thrombocytopenia in chronic liver disease.32 Platelets 
were also reported to improve liver fibrosis and ac-
celerate liver regeneration.33 In patients with chronic 
hepatitis B with significant fibrosis receiving anti-viral 
therapy, the increase of platelets was associated with the 
Table 2. Characteristics of 17 patients treated with 
pemafibrate
Male/Female 10:7
Age (years) 63 (27–81)
Height (m) 1.7 (1.5–1.8)
Pre-treatment body weight (kg) 70.6 (48.6–101.7)
Pre-treatment BMI (kg/m2)* 26.8 (19.2–33.8)
Patients of BMI > 25 kg/m2 11 (64.7%)
Comorbidities
 T2DM 10 (58.8)
 Chronic hepatitis B† 1 (5.9)
 CAD 1 (5.9)
 IBD 1 (5.9)
 GERD 1 (5.9)
 Other‡ 1 (5.9)
Imaging modalities
 US 10 (58.8)
 CT 6 (35.3)
 MRI 1 (5.9)
Biopsy proven NASH 3 (17.6)
Pre-treatment laboratory values
 TG (mg/dL) 300.5 ± 22.5
 HDL-cholesterol (mg/dL) 46.5 ± 2.4
 LDL-cholesterol (mg/dL) 109.5 ± 10.6
 AST (U/L) 43.8 ± 5.4
 ALT (U/L) 57.5 ± 8.8
 GGT (U/L) 63.9 ± 10.3
 FIB-4 index 1.7 ± 0.2
 APRI 0.7 ± 0.1
 HbA1c (%) 7.7 ± 0.5
Concomitant medications
 DPP4 inhibitor 6 (35.3)
 Metformin 3 (17.6)
 SGLT2 inhibitor 2 (11.8)
 EPA 3 (17.6)
 Statin 5 (29.4)
 Ezetimibe 7 (41.2)
 UDCA 4 (23.5)
Dosage of pemafibrate
 0.1 mg 3 (17.6)
 0.2 mg 12 (70.6)
 0.4 mg 2 (11.8)
Duration of pemafibrate  
administration (months)
6.1 (3.0–19.1)
APRI, aspartate aminotransferase to platelet ratio index; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; BMI, 
body mass index; CAD, coronary artery disease; CT, computed 
tomography; DPP4, dipeptidyl peptidase-4; EPA, eicosapentaenoic 
acid; GERD, gastroesophageal ref lux disease; GGT, gamma-
glutamyl transpeptidase; HDL, high-density lipoprotein; IBD, 
inflammatory bowel disease; LDL, low-density lipoprotein; MRI, 
the magnetic resonance of imaging; SGLT2, sodium-glucose 
cotransporter 2; T2DM, type 2 diabetes mellitus; TG, triglyceride; 
UDCA, ursodeoxycholic acid; US, ultrasonography. *BMI cannot 
be calculated in two patients because of a lack of body hight. †HBV 
DNA is controlled under the detective level by nucleotide analog 
treatment. ‡Ovarian insufficiency. Data are expressed as median 
(range) or mean ± SEM.
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Fig. 3. Laboratory data during pemafibrate treatment for six months. (A) Triglyceride, (B) High-density lipoprotein cholesterol, (C) 
Low-density lipoprotein cholesterol, (D) Aspartate aminotransferase, (E) Alanine aminotransferase, (F) Gamma-glutamyl transferase. 
Data are expressed as mean with a standard error of the mean (SEM). *P < 0.05, **P < 0.01
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improvement of liver fibrosis.34 In our study, pemafi-
brate decreased the AST level (–35%) and increased 
platelet count (+10%). AST and platelet counts could 
not demonstrate significant changes independently; 
however, APRI was significantly decreased in the sixth 
month after treatment with pemafibrate. Decreasing 
APRI can be considered as an improvement in hepatic 
inflammation and liver fibrosis. This significant change 
was not found by other medications.
It has already known that metformin can improve 
biochemical and metabolic features in NAFLD.35 In 
our study, three patients had already taken metformin. 
There was no significant difference between patients 
with or without metformin. Metformin also has an 
effect of improving BMI via improvement in insulin 
resistance. Although BMI did not decrease in our three 
patients for six months (29.5 ± 0.3 to 29.1 ± 0.3 kg/m2), 
the synergic effect of metformin and pemafibrate might 
be achieved by more prolonged treatment.
SGLT2 inhibitors have also been reported to have 
favorable effects on NAFLD in T2DM patients.36 In our 
study, there were only two patients who had taken an 
Fig. 4. The differences in BMI and HbA1c between pre-treatment and the sixth month.
(A) Body mass index did not change between pre-treatment and the sixth month. (B) HbA1c did not change between pre-treatment and 
the sixth month. Data are expressed as mean with a standard error of the mean (SEM). *P < 0.05. n.s., not significant.
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SGLT2 inhibitor. There were no significant differences 
in the data obtained in this study. The other medications 
also did not demonstrate any differences in the data 
between patients with or without it.
Dose dependency of pemafibrate was also evalu-
ated; however, there were no statistically significant 
differences in LFTs among three dosages because of the 
small sample size.
Among the excluded patients, four discontinued 
pemafibrate. One patient stopped it because of suc-
cessful weight reduction, another patient stopped it for 
unknown reasons, and two were due to the elevation 
of LFTs. One patient experienced AST 59 U/L to 119 
U/L and ALT 55 U/L to 113 U/L after 12 weeks from 
administration. Another patient experienced AST 69 
U/L to 201 U/L, ALT56 U/L to 181 U/L, and GGT 198 
U/L to 677 U/L after 19 weeks from administration. 
Both were administered 0.2 mg bid. The adverse events 
on LFTs reported in the phase 3 trial were in only two 
patients (3.7%) complicated with GGT > three times the 
upper normal limit. There is no appropriate explanation 
for this discrepancy for now. Because of these results, 
we should pay much more attention to LFTs for at least 
four months after administration in order to gather more 
Fig. 5. Laboratory data during pemafibrate treatment in biopsy-proven NASH patients.
(A) Triglyceride, (B) Aspartate aminotransferase, (C) Alanine aminotransferase, (D) Gamma-glutamyl transferase. Data are expressed 
as mean with a standard error of the mean (SEM).
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information and experience.
Our study had some limitations. It was a small size 
retrospective observational study of only six months’ 
duration, and there was missing data that needed to 
be compensated by using median values. Selection 
bias could not be avoided because this study enrolled 
only imaging-proven NAFLD patients retrospectively. 
However, these data are consistent with other experi-
mental and trial data.9, 12 For this reason, we believe 
that we could demonstrate the efficacy of pemafibrate 
for NAFLD. Liver biopsy is undoubtedly the gold 
standard for diagnosing NASH at present. In this study, 
only three patients had a biopsy performed on them. 
Although it was difficult to obtain statistical differences, 
pemafibrate could also decrease LFTs in biopsy-proven 
NASH in a similar fashion to the patients that had 
NAFLD. Whether pemafibrate can reduce fibrosis or 
not was not evaluated by biopsy in this study. In Japan, 
clinical trials for the antifibrotic effect of pemafibrate on 
NAFLD are ongoing. The results are expected to eluci-
date the further efficacy of pemafibrate for NAFLD.
In conclusion, we demonstrated that pemafibrate, 
the new SPPARMα, dramatically ameliorated the values 
of LFTs in patients with NAFLD. Pemafibrate has the 
potential to be the first standard medication of NAFLD.
The authors declare no conflict of interest.
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